Equities

Molecular Templates Inc

MTEM:NAQ

Molecular Templates Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.35
  • Today's Change-0.01 / -0.74%
  • Shares traded39.51k
  • 1 Year change-80.10%
  • Beta1.1562
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Molecular Templates Inc share price to rise to 18.00 in the next year from the last price of 1.35.
High1,233.3%18.00
Med1,233.3%18.00
Low1,233.3%18.00

Earnings history & estimates in USD

On Aug 14, 2024, Molecular Templates Inc reported 2nd quarter 2024 losses of -1.23 per share. This result exceeded the -1.44 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 56.84%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+41.10%
Molecular Templates Inc reported annual 2023 losses of -1.80 per share on Mar 29, 2024.
Average growth rate+24.07%
More ▼

Revenue history & estimates in USD

Molecular Templates, Inc. had 2nd quarter 2024 revenues of 572.00k. This bettered the 430.00k estimate of the one analyst covering the company. This was 98.44% below the prior year's 2nd quarter results.
Average growth rate-8.65%
Molecular Templates, Inc. had revenues for the full year 2023 of 57.31m. This was 190.10% above the prior year's results.
Average growth rate+57.78%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.